2 results match your criteria: "Louisiana State University's Pennington Biomedical Research Centre[Affiliation]"
Neurology
May 2022
From the Department of Epidemiology (I.D.A.-D., L.A.B.), Tulane University School of Public Health and Tropical Medicine; Department of Medicine (C.F.A., L.A.B.), Tulane University School of Medicine, New Orleans, LA; Department of Psychology (D.J.L.) and New Jersey Institute for Successful Aging (D.J.L.), School of Osteopathic Medicine, Rowan University, Glassboro, NJ; Louisiana State University's Pennington Biomedical Research Centre (O.T.C.), Baton Rouge; Departments of Medicine (V.B.K.) and Anatomy and Neurobiology (R.A.), Boston University School of Medicine; Department of Computer Science and Faculty of Computing and Data Sciences (V.B.K.), Boston University, MA; Department of Epidemiology (S.F.S.), Rollins School of Public Health, Emory University, Atlanta, GA; and Boston University Alzheimer's Disease Center (R.A.), MA.
Background And Objectives: Carotid intima-media thickness (c-IMT) is a measurement of atherosclerosis, a progressive disease that develops as early as childhood and has been linked with cognitive impairment and dementia in the elderly. However, the relationship between c-IMT and midlife cognitive function and the race and social disparities in this relationship remain unclear. We examined the association between c-IMT and cognitive function in midlife among Black and White participants from a semirural community-based cohort in Bogalusa, Louisiana.
View Article and Find Full Text PDFEBioMedicine
August 2019
Louisiana State University's Pennington Biomedical Research Centre, Baton Rouge, LA, USA.
Background: Severe energy deficits during military operations, produced by significant increases in exercise and limited dietary intake, result in conditions that degrade lean body mass and lower-body muscle function, which may be mediated by concomitant reductions in circulating testosterone.
Methods: We conducted a three-phase, proof-of-concept, single centre, randomised, double-blind, placebo-controlled trial (CinicalTrials.gov, NCT02734238) of non-obese men: 14-d run-in, free-living, eucaloric diet phase; 28-d live-in, 55% exercise- and diet-induced energy deficit phase with (200 mg testosterone enanthate per week, Testosterone, n = 24) or without (Placebo, n = 26) exogenous testosterone; and 14-d recovery, free-living, ad libitum diet phase.